SCHEMBL5090791

SCHEMBL5090791

CCOC(=O)Nc1ccc(OCc2cc(F)cc(F)c2)cc1N

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNQ2 O43526 6/20 0.59
KCNQ3 O43525 5/20 0.59
KCNQ4 P56696 2/20 0.59
KCNQ5 Q9NR82 2/20 0.59
CYP1A2 P05177 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
ABCB11 O95342 1/20 0.46
ESR1 P03372 1/20 0.46
CYP3A4 P08684 1/20 0.46
HTR1A P08908 1/20 0.46
ADRA2A P08913 1/20 0.46
ADORA3 P0DMS8 1/20 0.46
CYP2D6 P10635 1/20 0.46
ALOX15 P16050 1/20 0.46
NFKB1 P19838 1/20 0.46
TBXA2R P21731 1/20 0.46
MAPK1 P28482 1/20 0.46
CASP1 P29466 1/20 0.46
SHMT2 P34897 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5090811 0.91 KCNQ2 (0.65) KCNQ2KCNQ3KCNQ4KCNQ5CYP1A2
SCHEMBL5087357 0.90 MAOB (0.57) KCNQ2KCNQ3KCNQ4KCNQ5MAOB
SCHEMBL5090792 0.87 KCNQ2 (0.55) KCNQ2KCNQ3KCNQ4KCNQ5CYP1A2
SCHEMBL5090320 0.86 ALDH1A1 (0.53) KCNQ2KCNQ3KCNQ4KCNQ5CYP1A2
SCHEMBL5089465 0.86 CYP1A2 (0.55) KCNQ2KCNQ3KCNQ4KCNQ5CYP1A2
SCHEMBL5096507 0.84 KCNQ2 (0.54) KCNQ2KCNQ3KCNQ4KCNQ5CYP1A2
SCHEMBL5089259 0.84 MAOB (0.52) KCNQ2KCNQ3KCNQ4KCNQ5CYP1A2
SCHEMBL5087377 0.84 MAOA (0.52) KCNQ2KCNQ3KCNQ4KCNQ5CYP1A2
SCHEMBL14097681 0.84 CYP1A2 (0.56) KCNQ2KCNQ3KCNQ4KCNQ5CYP1A2
SCHEMBL5087380 0.83 KCNQ2 (0.57) KCNQ2KCNQ3KCNQ4KCNQ5CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080188561-A1 N-[2-AMINO-4-(PHENYLMETHOXY)PHENYL] AMIDES AND RELATED COMPOUNDS AS POTASSIUM CHANNEL MODULATORS JPMORGAN CHASE BANK, N.A. 2008-08-07 US claimed
US-8722929-B2 N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators VALEANT PHARMACEUTICALS INTERNATIONAL (US) 2014-05-13 US disclosed
US-20080188561-A1 N-[2-AMINO-4-(PHENYLMETHOXY)PHENYL] AMIDES AND RELATED COMPOUNDS AS POTASSIUM CHANNEL MODULATORS JPMORGAN CHASE BANK, N.A. 2008-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188561-A1 N-[2-AMINO-4-(PHENYLMETHOXY)PHENYL] AMIDES AND RELATED COMPOUNDS AS POTASSIUM CHANNEL MODULATORS KCNB2, KCNJ2, KCNA2 KCNQ2 9/4885KCNQ3 32/4885KCNQ4 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.